Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Other Items
Gensight Biologics SA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Other Items
€82k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Items
€81.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Other Items
€24.1m
|
CAGR 3-Years
348%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Items
€90k
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Other Items
€9.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other Items
€18.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
40%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Other Items?
Other Items
82k
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Other Items amounts to 82k EUR.
What is Gensight Biologics SA's Other Items growth rate?
Other Items CAGR 5Y
33%
Over the last year, the Other Items growth was -75%.
You don't have any saved screeners yet